Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""BONE density"" wg kryterium: Temat


Starter badań:

Tytuł:
Updated trabecular bone score accounting for the soft tissue thickness (TBS TT ) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis.
Autorzy:
Hans D; Interdisciplinary Center of Bone Diseases, Lausanne University Hospital and Lausanne University, Av. Pierre Decker 4, 1011, Lausanne, Switzerland. .
Shevroja E; Interdisciplinary Center of Bone Diseases, Lausanne University Hospital and Lausanne University, Av. Pierre Decker 4, 1011, Lausanne, Switzerland.
McDermott M; Amgen Inc, Thousand Oaks, CA, USA.
Huang S; Amgen Inc, Thousand Oaks, CA, USA.
Kim M; Amgen Inc, Thousand Oaks, CA, USA.
McClung M; Oregon Osteoporosis Center, Portland, OR, USA.; Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia.
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Dec; Vol. 33 (12), pp. 2517-2525. Date of Electronic Publication: 2022 Sep 17.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Female ; Humans ; Cancellous Bone ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Bone Density ; Absorptiometry, Photon/methods ; Lumbar Vertebrae ; Freedom
Czasopismo naukowe
Tytuł:
Two-year risedronate treatment for osteoporosis in patients with esophageal varices: a non-randomized clinical trial.
Autorzy:
Santos LAA; Internal Medicine Department, Botucatu Medical School, Gastroenterology Division-São Paulo State University (UNESP), Rubião Júnior s/n, Botucatu, SP, CEP 18618-687, Brazil.
Lima TB; Internal Medicine Department, Botucatu Medical School, Gastroenterology Division-São Paulo State University (UNESP), Rubião Júnior s/n, Botucatu, SP, CEP 18618-687, Brazil.
de Carvalho Nunes HR; Public Health Department, Botucatu Medical School, São Paulo State University (UNESP), Botucatu, Brazil.
Qi X; General Hospital of Shenyang Military Command, Liaoning, Sheng, China.
Romeiro FG; Internal Medicine Department, Botucatu Medical School, Gastroenterology Division-São Paulo State University (UNESP), Rubião Júnior s/n, Botucatu, SP, CEP 18618-687, Brazil. .
Pokaż więcej
Źródło:
Hepatology international [Hepatol Int] 2022 Dec; Vol. 16 (6), pp. 1458-1467. Date of Electronic Publication: 2022 Jun 29.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Esophageal and Gastric Varices*/complications
Bone Density Conservation Agents*/therapeutic use
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/complications
Osteoporosis*/drug therapy
Osteoporosis*/chemically induced
Esophagitis*/chemically induced
Esophagitis*/complications
Esophagitis*/drug therapy
Humans ; Risedronic Acid/therapeutic use ; Gastrointestinal Hemorrhage/complications ; Bone Density ; Liver Cirrhosis/complications ; Liver Cirrhosis/drug therapy
Czasopismo naukowe
Tytuł:
Denosumab treatment is associated with decreased cortical porosity and increased bone density and strength at the proximal humerus of ovariectomized cynomolgus monkeys.
Autorzy:
Haider IT; Human Performance Lab, Canada; McCaig Institute for Bone and Joint Health, University of Calgary, Canada.
Sawatsky A; Human Performance Lab, Canada; McCaig Institute for Bone and Joint Health, University of Calgary, Canada.
Zhu Y; McCaig Institute for Bone and Joint Health, University of Calgary, Canada.
Page R; Human Performance Lab, Canada; McCaig Institute for Bone and Joint Health, University of Calgary, Canada.
Kostenuik PJ; School of Dentistry, University of Michigan, United States.
Boyd SK; McCaig Institute for Bone and Joint Health, University of Calgary, Canada.
Edwards WB; Human Performance Lab, Canada; McCaig Institute for Bone and Joint Health, University of Calgary, Canada. Electronic address: .
Pokaż więcej
Źródło:
Bone [Bone] 2022 Nov; Vol. 164, pp. 116517. Date of Electronic Publication: 2022 Aug 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Alendronate/pharmacology ; Alendronate/therapeutic use ; Animals ; Bone Density ; Denosumab/pharmacology ; Denosumab/therapeutic use ; Epiphyses ; Female ; Humans ; Humerus/diagnostic imaging ; Macaca fascicularis ; Ovariectomy ; Porosity ; X-Ray Microtomography
Czasopismo naukowe
Tytuł:
Triphasic calcium-based implant material resorbs and is replaced with bone in ovariectomized rats with or without bisphosphonate treatment.
Autorzy:
Shaul J; AgNovos Healthcare, Rockville, Maryland, USA.
Hill R; AgNovos Healthcare, Rockville, Maryland, USA.
Bruder S; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Tilton A; AgNovos Healthcare, Rockville, Maryland, USA.
Howe J; AgNovos Healthcare, Rockville, Maryland, USA.; Department of Orthopedic Surgery, University of Vermont, Burlington, Vermont, USA.
Pokaż więcej
Źródło:
Journal of orthopaedic research : official publication of the Orthopaedic Research Society [J Orthop Res] 2022 Oct; Vol. 40 (10), pp. 2271-2280. Date of Electronic Publication: 2022 Jan 25.
Typ publikacji:
Journal Article; Randomized Controlled Trial, Veterinary; Research Support, Non-U.S. Gov't
MeSH Terms:
Alendronate*/pharmacology
Alendronate*/therapeutic use
Bone Density Conservation Agents*/pharmacology
Bone Density Conservation Agents*/therapeutic use
Animals ; Bone Density ; Calcium ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; Female ; Ovariectomy ; Rats ; X-Ray Microtomography
Czasopismo naukowe
Tytuł:
Orchestrated delivery of PTH [1-34] followed by zoledronic acid prevents radiotherapy-induced bone loss but does not abrogate marrow damage.
Autorzy:
Sweeney-Ambros AR; Department of Orthopedic Surgery, SUNY Upstate Medical University, Syracuse, New York, USA.
Biggs AE; Department of Orthopedic Surgery, SUNY Upstate Medical University, Syracuse, New York, USA.
Zimmerman ND; Department of Orthopedic Surgery, SUNY Upstate Medical University, Syracuse, New York, USA.
Mann KA; Department of Orthopedic Surgery, SUNY Upstate Medical University, Syracuse, New York, USA.
Damron TA; Department of Orthopedic Surgery, SUNY Upstate Medical University, Syracuse, New York, USA.
Oest ME; Department of Orthopedic Surgery, SUNY Upstate Medical University, Syracuse, New York, USA.
Pokaż więcej
Źródło:
Journal of orthopaedic research : official publication of the Orthopaedic Research Society [J Orthop Res] 2022 Dec; Vol. 40 (12), pp. 2843-2855. Date of Electronic Publication: 2022 Mar 25.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*/pharmacology
Bone Diseases, Metabolic*/drug therapy
Humans ; Mice ; Animals ; Zoledronic Acid/pharmacology ; Bone Marrow ; Parathyroid Hormone ; Bone Density
Czasopismo naukowe
Tytuł:
Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis.
Autorzy:
Suzuki T; Division of Nephrology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan. .
Mizobuchi M; Division of Nephrology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Yoshida S; Division of Nephrology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Terado N; Division of Nephrology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Aoki S; Division of Nephrology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Sato N; Division of Nephrology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Honda H; Division of Nephrology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Dec; Vol. 33 (12), pp. 2649-2652. Date of Electronic Publication: 2022 Aug 18.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Polycystic Kidney, Autosomal Dominant*/drug therapy
Osteoporosis*/drug therapy
Osteoporosis*/etiology
Osteoporosis*/metabolism
Bone Density Conservation Agents*/therapeutic use
Bone Diseases*
Renal Insufficiency, Chronic*/therapy
Renal Insufficiency, Chronic*/drug therapy
Humans ; Adult ; Bone Density ; Antibodies, Monoclonal/therapeutic use ; Renal Dialysis
Czasopismo naukowe
Tytuł:
The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy: real-world data.
Autorzy:
Abdel-Razeq H; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan. .; School of Medicine, University of Jordan, Queen Rania Al Abdullah Street, P.O. Box 1269, Amman, 11941, Jordan. .
Al-Rasheed U; Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
Mashhadani N; Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
Al-Ibraheem A; Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan.
Abdel-Razeq R; Istishari Hospital, Amman, Jordan.
Jaradeh SA; School of Medicine, University of Jordan, Queen Rania Al Abdullah Street, P.O. Box 1269, Amman, 11941, Jordan.
Mansour R; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Bater R; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Tbayshat S; Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Pokaż więcej
Źródło:
Irish journal of medical science [Ir J Med Sci] 2022 Dec; Vol. 191 (6), pp. 2511-2515. Date of Electronic Publication: 2022 Jan 28.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/chemically induced
Bone Diseases, Metabolic*
Humans ; Female ; Aged ; Bone Density ; Postmenopause ; Retrospective Studies ; Aromatase Inhibitors/adverse effects ; Hormones/pharmacology
Czasopismo naukowe
Tytuł:
Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.
Autorzy:
Langdahl B; Department of Endocrinology, Aarhus University Hospital, Aarhus, Denmark. .
Hofbauer LC; Technische Universität Dresden, Dresden, Germany.
Ferrari S; Geneva University Hospital, Geneva, Switzerland.
Wang Z; Amgen Inc., Thousand Oaks, CA, USA.
Fahrleitner-Pammer A; Medical University of Graz, Graz, Austria.
Gielen E; University Hospital Leuven, Leuven, Belgium.
Lakatos P; Semmelweis University, Budapest, Hungary.
Czerwinski E; Krakow Medical Centre, Krakow, Poland.
Gimeno EJ; Hospital Universitario Quiron Salud Madrid, Universidad Europea, Madrid, Spain.
Timoshanko J; UCB Pharma, Slough, UK.
Oates M; Amgen Inc., Thousand Oaks, CA, USA.
Libanati C; UCB Pharma, Brussels, Belgium.
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Dec; Vol. 33 (12), pp. 2527-2536. Date of Electronic Publication: 2022 Sep 29.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Bone Density Conservation Agents*/adverse effects
Osteoporotic Fractures*/chemically induced
Osteoporosis, Postmenopausal*/complications
Humans ; Female ; Denosumab/adverse effects ; Double-Blind Method ; Bone Density
Czasopismo naukowe
Tytuł:
The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence.
Autorzy:
Chandran M; Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore, .
Pokaż więcej
Źródło:
Archives of endocrinology and metabolism [Arch Endocrinol Metab] 2022 Nov 11; Vol. 66 (5), pp. 724-738.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Fractures, Bone*
Osteoporosis, Postmenopausal*/drug therapy
Humans ; Female ; Teriparatide/therapeutic use ; Denosumab/therapeutic use ; Bone Density ; Diphosphonates/therapeutic use
Czasopismo naukowe
Tytuł:
Anabolic therapy for osteoporosis: update on efficacy and safety.
Autorzy:
Bandeira L; Universidade Federal de São Paulo, São Paulo, SP, Brasil.; Grupo Fleury, Recife, PE, Brasil.
Lewiecki EM; New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA, .
Pokaż więcej
Źródło:
Archives of endocrinology and metabolism [Arch Endocrinol Metab] 2022 Nov 11; Vol. 66 (5), pp. 707-716.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Osteoporosis*/drug therapy
Bone Density Conservation Agents*/adverse effects
Bone Resorption*/chemically induced
Bone Resorption*/drug therapy
Humans ; Teriparatide/therapeutic use ; Teriparatide/pharmacology ; Bone Density
Czasopismo naukowe
Tytuł:
Long-term consequences of osteoporosis therapy with denosumab.
Autorzy:
Bandeira F; Divisão de Endocrinologia e Diabetes, Hospital Agamenon Magalhães, Universidade de Pernambuco (UPE), Faculdade de Ciências Médicas, Recife, PE, Brasil, .
de Oliveira LB; Divisão de Endocrinologia e Diabetes, Hospital Agamenon Magalhães, Universidade de Pernambuco (UPE), Faculdade de Ciências Médicas, Recife, PE, Brasil.
Bilezikian JP; Department of Medicine, Endocrinology Division, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Pokaż więcej
Źródło:
Archives of endocrinology and metabolism [Arch Endocrinol Metab] 2022 Nov 11; Vol. 66 (5), pp. 717-723.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Osteoporosis*/drug therapy
Bone Density Conservation Agents*/adverse effects
Osteoporosis, Postmenopausal*
Humans ; Female ; Denosumab/therapeutic use ; Denosumab/pharmacology ; Diphosphonates/therapeutic use ; Bone Density ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł:
Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO).
Autorzy:
Silva BC; Unidade de Endocrinologia, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brasil.; Unidade de Endocrinologia, Hospital Felício Rocho, Belo Horizonte, MG, Brasil.; Departamento de Medicina, Centro Universitário de Belo Horizonte (UNI-BH), Belo Horizonte, MG, Brasil, .; Member of the Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM).
Madeira M; Divisão de Endocrinologia e Metabolismo, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.; Member of the Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM).
d'Alva CB; Departamento de Medicina Clínica, Universidade Federal do Ceará (UFC), Fortaleza, CE, Brasil.; Member of the Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM).
Maeda SS; Unidade de Endocrinologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil.; Member of the Associação Brasileira de Avaliação Óssea e Osteometabolismo (ABRASSO).
de Holanda NCP; Divisão de Endocrinologia e Metabolismo, Universidade Federal da Paraíba, João Pessoa, PB, Brasil.; Member of the Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM).
Ohe MN; Unidade de Endocrinologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil.; Member of the Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM).
Szejnfeld V; Divisão de Reumatologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil.; Member of the Associação Brasileira de Avaliação Óssea e Osteometabolismo (ABRASSO).
Zerbini CAF; Centro Paulista de Investigação Clínica, São Paulo, SP, Brasil.; Member of the Associação Brasileira de Avaliação Óssea e Osteometabolismo (ABRASSO).
de Paula FJA; Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.; Member of the Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM).; Member of the Associação Brasileira de Avaliação Óssea e Osteometabolismo (ABRASSO).
Bandeira F; Divisão de Endocrinologia e Metabolismo, Faculdade de Medicina, Universidade de Pernambuco, Recife, PE, Brasil.; Member of the Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM).
Pokaż więcej
Źródło:
Archives of endocrinology and metabolism [Arch Endocrinol Metab] 2022 Nov 11; Vol. 66 (5), pp. 591-603. Date of Electronic Publication: 2022 Oct 03.
Typ publikacji:
Consensus Development Conference
MeSH Terms:
Osteoporosis, Postmenopausal*/complications
Osteoporosis, Postmenopausal*/drug therapy
Bone Density Conservation Agents*
Anabolic Agents*/therapeutic use
Osteoporosis*/drug therapy
Osteoporotic Fractures*/etiology
Osteoporotic Fractures*/prevention & control
Osteoporotic Fractures*/drug therapy
Humans ; Female ; Brazil ; Bone Density
Konferencja
Tytuł:
Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
Autorzy:
Cosman F; Division of Endocrinology/Department of Medicine, Columbia University, New York, NY, USA.
Huang S; Amgen Inc., Thousand Oaks, CA, USA.
McDermott M; Amgen Inc., Thousand Oaks, CA, USA.
Cummings SR; San Francisco Coordinating Center, California Pacific Medical Center Research Institute and University of California, San Francisco, CA, USA.
Pokaż więcej
Źródło:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2022 Nov; Vol. 37 (11), pp. 2112-2120. Date of Electronic Publication: 2022 Oct 12.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Bone Density Conservation Agents*
Osteoporosis*/drug therapy
Osteoporosis, Postmenopausal*/drug therapy
Osteoporotic Fractures*/prevention & control
Spinal Fractures*/drug therapy
Spinal Fractures*/epidemiology
Female ; Humans ; Bone Density ; Denosumab ; Fracture Fixation ; Freedom
Czasopismo naukowe
Tytuł:
Denosumab for Prevention of Acute Onset Immobilization-Induced Alterations of Bone Turnover: A Randomized Controlled Trial.
Autorzy:
Wadiura LI; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
Butylina M; Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria.
Reinprecht A; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
Aretin MB; Pharmacy Department, General Hospital of Vienna, Vienna, Austria.
Mischkulnig M; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
Gleiss A; Center of Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Pietschmann P; Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria.
Kerschan-Schindl K; Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna, Vienna, Austria.
Pokaż więcej
Źródło:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2022 Nov; Vol. 37 (11), pp. 2156-2164. Date of Electronic Publication: 2022 Sep 23.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Denosumab*
Bone Density Conservation Agents*/therapeutic use
Humans ; Bone Density ; Calcium/pharmacology ; Biomarkers/metabolism ; Bone Remodeling ; Minerals
Czasopismo naukowe
Tytuł:
Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis.
Autorzy:
Okawa T; Okawa Orthopaedic Surgery Hospital, Domyojimachi 6-12-34, Fujiidera, Osaka, 583-0012, Japan. .
Okawa M; Okawa Orthopaedic Surgery Hospital, Domyojimachi 6-12-34, Fujiidera, Osaka, 583-0012, Japan.
Koike T; Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine, Abenoku Asahimachi 1-4-3, Osaka, 545-8585, Japan.; Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Nishimurogun Shirahamacho 1447, Wakayama, 649-2211, Japan.
Pokaż więcej
Źródło:
Journal of bone and mineral metabolism [J Bone Miner Metab] 2022 Nov; Vol. 40 (6), pp. 960-967. Date of Electronic Publication: 2022 Aug 08.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Osteoporosis*/drug therapy
Osteoporosis, Postmenopausal*/drug therapy
Female ; Humans ; Denosumab/therapeutic use ; Postmenopause ; Japan ; Bone Density ; Risk Factors
Czasopismo naukowe
Tytuł:
Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.
Autorzy:
Eastell R; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Vittinghoff E; Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Lui LY; Research Institute, California Pacific Medical Center, San Francisco, CA, USA.
Ewing SK; Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Schwartz AV; Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Bauer DC; Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Black DM; Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Bouxsein ML; Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center and Department of Orthopedic Surgery, Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2022 Nov; Vol. 37 (11), pp. 2121-2131. Date of Electronic Publication: 2022 Oct 07.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Hip Fractures*/drug therapy
Osteoporosis*/drug therapy
Humans ; Bone Density ; Denosumab/therapeutic use ; Diphosphonates/therapeutic use
Czasopismo naukowe
Tytuł:
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.
Autorzy:
Mazziotti G; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy.; Endocrinology, Diabetology and Andrology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Pedersini R; Medical Oncology Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.
Vena W; Endocrinology, Diabetology and Andrology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.; Medical Oncology Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.; Endocrinology and Diabetology Center, Humanitas Gavazzeni-Castelli, Bergamo, Italy.
Cosentini D; Medical Oncology Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.
Carrone F; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy.; Endocrinology, Diabetology and Andrology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Pigni S; Endocrinology, Diabetology and Andrology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Simoncini EL; Medical Oncology Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.
Torrisi R; Cancer Center IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Zambelli A; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy.; Cancer Center IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Farina D; Radiology Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Balzarini L; Department of Radiology, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Lania AG; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20090, Pieve Emanuele, MI, Italy. .; Endocrinology, Diabetology and Andrology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy. .
Berruti A; Medical Oncology Unit, ASST Spedali Civili Di Brescia, Brescia, Italy.; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Pokaż więcej
Źródło:
Calcified tissue international [Calcif Tissue Int] 2022 Nov; Vol. 111 (5), pp. 466-474. Date of Electronic Publication: 2022 Jul 28.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*/pharmacology
Breast Neoplasms*/drug therapy
Fractures, Bone*/drug therapy
Spinal Fractures*/drug therapy
Spinal Fractures*/prevention & control
Aromatase Inhibitors/adverse effects ; Bone Density ; Child ; Child, Preschool ; Denosumab ; Diphosphonates/therapeutic use ; Female ; Humans ; Prospective Studies ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł:
Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk.
Autorzy:
Shin JW; Department of Orthopedic Surgery, National Health Insurance Service Ilsan Hospital, 100 Ilsan-ro, Goyang, 10444, Republic of Korea.; Department of Orthopedic Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
He Q; Department of Orthopedic Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Suk YJ; Department of Orthopedic Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Kim SH; Department of Orthopedic Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Kim HS; Department of Orthopedic Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. .
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Nov; Vol. 33 (11), pp. 2409-2416. Date of Electronic Publication: 2022 Aug 04.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Bone Density Conservation Agents*
Osteoporosis, Postmenopausal*/chemically induced
Osteoporosis, Postmenopausal*/complications
Osteoporosis, Postmenopausal*/drug therapy
Osteoporotic Fractures*/chemically induced
Osteoporotic Fractures*/prevention & control
Bone Density ; Denosumab/therapeutic use ; Female ; Humans ; Retrospective Studies ; Teriparatide
Czasopismo naukowe
Tytuł:
Bone loss induced by cancer treatments in breast and prostate cancer patients.
Autorzy:
Castañeda S; Department of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Catedra UAM-Roche, EPID-Future, Universidad Autónoma de Madrid, Madrid, Spain.
Casas A; Department of Medical Oncology, Hospital Virgen del Rocío, Seville, Spain.
González-Del-Alba A; Department of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Martínez-Díaz-Guerra G; Department of Endocrinology and Nutrition, Instituto de Investigación imas12, Universidad Complutense, Hospital 12 de Octubre, Madrid, Spain.
Nogués X; Department of Internal Medicine, Hospital del Mar, Hospital del Mar Research Institute (IMIM), Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Universidad Pompeu Fabra, Barcelona, Spain.
Ojeda Thies C; Department of Traumatology and Orthopedic Surgery, Hospital Universitario, 12 de Octubre, Madrid, Spain.
Torregrosa Suau Ó; Department of Internal Medicine, Hospital General Universitario de Elche, Alicante, Spain.
Rodríguez-Lescure Á; Department of Medical Oncology, Hospital General Universitario de Elche, Camino de la Almazara, 11, 03202, Alicante, Spain. .
Pokaż więcej
Źródło:
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2022 Nov; Vol. 24 (11), pp. 2090-2106. Date of Electronic Publication: 2022 Jul 02.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Density Conservation Agents*/adverse effects
Osteoporosis*/chemically induced
Osteoporosis*/therapy
Prostatic Neoplasms*/complications
Prostatic Neoplasms*/therapy
Bone Density ; Breast ; Humans ; Male
Czasopismo naukowe
Tytuł:
Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis.
Autorzy:
Ebina K; Department of Musculoskeletal Regenerative Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan. .; Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan. .
Etani Y; Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Tsuboi H; Department of Orthopaedic Surgery, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Kita-ku, Sakai, 591-8025, Japan.
Nagayama Y; Nagayama Rheumatology and Orthopaedic Clinic, 4-3-25 Hiokisounishi-machi, Higashi-ku, Sakai, 599-8114, Japan.
Kashii M; Department of Orthopaedic Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka, Osaka, 560-8565, Japan.
Miyama A; Department of Orthopaedic Surgery, Osaka Toneyama Medical Center, 5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan.
Kunugiza Y; Department of Orthopaedic Surgery, Japan Community Health Care Organization, Hoshigaoka Medical Center, 4-8-1 Hoshigaoka, Hirakata, Osaka, 573-8511, Japan.
Hirao M; Department of Orthopaedic Surgery, National Hospital Organization Osaka Minami Medical Center, 2-1 Kidohigashi, Kawachinagano, Osaka, 586-8521, Japan.
Okamura G; Department of Orthopaedic Surgery, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Kita-ku, Sakai, 591-8025, Japan.
Noguchi T; Department of Orthopaedic Surgery, National Hospital Organization Osaka Minami Medical Center, 2-1 Kidohigashi, Kawachinagano, Osaka, 586-8521, Japan.
Takami K; Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Goshima A; Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Miura T; Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Fukuda Y; Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Kurihara T; Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Okada S; Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Nakata K; Department of Health and Sport Sciences, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Pokaż więcej
Źródło:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2022 Nov; Vol. 33 (11), pp. 2441-2443. Date of Electronic Publication: 2022 Sep 06.
Typ publikacji:
Letter; Comment
MeSH Terms:
Bone Density Conservation Agents*/therapeutic use
Osteoporosis, Postmenopausal*/drug therapy
Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Bone Density ; Female ; Humans
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz